AI in Medicine News — 2026-10-05 (Mon) Evening News

Overview

- The three areas where we saw movement were diagnosis/imaging (FDA's AI bone age assessment tool, two ultrasound studies), drug discovery/trial management (subject screening, facility selection), and joint development with Japanese medical records AI. - For clinical decision support, there is one federally funded project for digital twins for ICUs. - There is only one regulatory move by the FDA that allows the product to be identified. The rest are policy announcements (the relationship with medical care is unclear from the headline).

Diagnosis/Image

- Pediatric bone age assessment AI: Reportedly cleared by FDA after pre-approval review. The measurement target is bone age. There are no performance numbers in the headline. - Carotid artery plaque: AI that predicts plaques that can cause stroke from ultrasound signals. Performance numbers and verification scale are unknown. - Thyroid cancer: AI that detects hidden progression (spread) from ultrasound images. Dual-center study. The detection rate is unknown. Not sure if it's facing backwards or forwards. - Oncology Overview Articles (CancerNetwork): Review articles covering the impact of AI on clinical trials, workflows, and outcomes. It is unknown whether this is new data or not.

Clinical decision support

It is still at the funding stage and clinical efficacy and performance have not been demonstrated.

Generation AI and medical documents/medical records

- Japanese medical record AI tool “Katanashi” (AIBORN) has formed a capital and business alliance with Medical Data Vision. Accuracy and implementation results are not in the headlines. - GENSHI AI, which develops a generative AI platform for medical settings, was selected for the entrepreneurship support program "1stRound". Performance and safety evaluation of the product is unknown.

Hospital management/medical provision system

- How to train hospital models: “Tunicate-inspired” AI trains hospital models without leaking patient data. Details of the technology and level of verification using actual data are unknown. - New medical center at the University of Texas in the US: SOM will create a design that incorporates AI and data (details can be found in Japan's activities). - A Korean AI healthcare company plans to display its products at an event in Abu Dhabi. Contents unknown.

Drug discovery/clinical trials

- Clinical trial site selection: An article explaining lookalike modeling using real-world data and care delivery signals (HIT Consultant). Performance data is not in the headline. - Nucleus Network: Screening trial volunteers with AI agents. The phase of the target trial and screening accuracy are unknown. Stage unknown. There are no statements in the heading that have been clinically verified, and reproducibility and prospective verification have not been confirmed. - The article related to RXRX is a theory that predicts that AI and machine learning will change drug discovery. Since evaluations and market forecasts are not covered, the details are omitted.

Medical device approval/regulation

- Pediatric bone age assessment AI: FDA clearance. Product name and application category are not listed in the heading. - U.S. “Superintelligence Force”: President Trump announces the members of the committee that will coordinate AI policy (NBC News). It is a policy framework, and its application to the medical field is unclear from the headline. Not applicable to approval, designation, or guidelines.

Safety/Error/Bias

- There are no headings that directly deal with accuracy errors/biases. - The article on hospital model learning focuses on technology to prevent patient data leaks (privacy). - It was reported that OpenAI fired an employee due to "inadequate handling of sensitive information." The relationship with medical information is unclear from the headline.

Research results (major journals)

No relevant information (The source of the headline is industry/commentary media, and publication in major magazines cannot be confirmed).

Japanese movements

- Ministry of Health, Labor and Welfare: A white paper reveals a roadmap showing changes in medical and nursing care settings due to AI and robots (DX Magazine). The specific details are unknown. - Capital and business alliance between AIBORN (Katanashi) and Medical Data Vision. - SUNABACO: Signed an MOU with Kurashiki Central Hospital's Clinical Medical Research Institute for joint development of medical physical AI. It is at the MOU stage and there are no deliverables yet. - GENSHI AI: Selected for the 15th "1stRound". - SOM: Designed a new medical center for the University of Texas (this is an American project, but was reported in Japanese media).

Remarks from VIPs

No relevant information (because the list of important people being tracked is empty).